Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study record page now displays a 403 Forbidden message instead of the study details, making the record inaccessible to users visiting the page.SummaryDifference19%

- Check15 days agoChange DetectedThe revision tag was updated from v3.6.6 to v3.7.0, indicating a deployment update; no study content changes are introduced.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a small update to the site's underlying system.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous v3.6.4; this appears to be a software version update with no visible changes to study details or content.SummaryDifference0.1%

- Check65 days agoChange DetectedThe revision tag was updated from v3.6.3 to v3.6.4, indicating a new content release.SummaryDifference0.1%

- Check72 days agoChange DetectedNew entries were added to the Study Record Dates for 2026-07-16, 2027-04-08, 2026-06-25, and 2026-06, and older dates 2025-07-20, 2026-05-04, 2025-07-09, and 2025-07 were removed. These changes update the historical timeline of the study record on the page.SummaryDifference0.3%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.